URT Stock Overview
Engages in the research and development of diagnostic tests for cancers. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Urteste S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł81.60 |
| 52 Week High | zł112.50 |
| 52 Week Low | zł79.80 |
| Beta | 0.13 |
| 11 Month Change | -13.19% |
| 3 Month Change | -16.56% |
| 1 Year Change | -7.27% |
| 33 Year Change | -14.98% |
| 5 Year Change | n/a |
| Change since IPO | -17.41% |
Recent News & Updates
Shareholder Returns
| URT | PL Biotechs | PL Market | |
|---|---|---|---|
| 7D | -7.5% | -4.1% | -3.1% |
| 1Y | -7.3% | -16.8% | -1.7% |
Return vs Industry: URT exceeded the Polish Biotechs industry which returned -16.8% over the past year.
Return vs Market: URT underperformed the Polish Market which returned -1.7% over the past year.
Price Volatility
| URT volatility | |
|---|---|
| URT Average Weekly Movement | 4.2% |
| Biotechs Industry Average Movement | 5.1% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in PL Market | 8.6% |
| 10% least volatile stocks in PL Market | 3.0% |
Stable Share Price: URT has not had significant price volatility in the past 3 months compared to the Polish market.
Volatility Over Time: URT's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | 28 | Grzegorz Stefanski | www.urteste.com |
Urteste S.A. engages in the research and development of diagnostic tests for cancers. It offers diagnostic tests for pancreas, prostate, kidney, colon, liver, biliary tract, stomach, lung, oesophagus, ovary, endometrium, blood, breast, and nervous system cancer. The company was incorporated in 2021 and is based in Gdansk, Poland.
Urteste S.A. Fundamentals Summary
| URT fundamental statistics | |
|---|---|
| Market cap | zł117.28m |
| Earnings (TTM) | -zł4.28m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-26.9x
P/E RatioIs URT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| URT income statement (TTM) | |
|---|---|
| Revenue | zł0 |
| Cost of Revenue | zł561.00k |
| Gross Profit | -zł561.00k |
| Other Expenses | zł3.72m |
| Earnings | -zł4.28m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 28, 2024
| Earnings per share (EPS) | -3.03 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did URT perform over the long term?
See historical performance and comparison